Results 11 to 20 of about 4,164 (194)

Romosozumab-Associated Recurrent Erythema Nodosum in Mixed Connective Tissue Disease. [PDF]

ACR Open Rheumatol
Objective The aim of this study was to describe recurrent erythema nodosum (EN) temporally associated with romosozumab in a patient with mixed connective tissue disease and to examine the biologic plausibility of this association in the context of Wnt/β‐catenin–mediated immune regulation.
Diaz Macip JL, Turcu I, Goranti J, Sivaguru S, Kodam SP, Afzal Z.   +5 more
europepmc   +2 more sources

Romosozumab Versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: An Overview of Systematic Reviews With Direct and Indirect Meta-Analyses. [PDF]

Int J Rheum Dis
ABSTRACT Aim To summarize the evidence of efficacy and safety of romosozumab compared to teriparatide for postmenopausal osteoporosis. Methods A literature search was performed in Medline, the Cochrane Library, CRD, and LILACS until November 2023. We included systematic reviews with meta‐analyses on the use of romosozumab compared to teriparatide in ...
Bandeira TFGS, Aguiar PM, Vianna CMM, Mosegui GBG, Lima TM.   +4 more
europepmc   +2 more sources

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk

Women's Health, 2022
Increased understanding of the Wnt signaling pathway has led to the development of romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis treatment.
Sian Yik Lim
doaj   +1 more source

The Real‐World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study

JBMR Plus, 2022
Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on bone mineral density (BMD) increase in real‐world clinical practice because its use has only been approved recently.
Hiroyuki Inose, Akane Ariga, Takayuki Motoyoshi, Kazuyuki Fukushima, Shoji Tomizawa, Tsuyoshi Kato, Kunihiko Takahashi, Toshitaka Yoshii, Atsushi Okawa   +8 more
doaj   +1 more source

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study

Osteoporosis and Sarcopenia, 2021
Objectives: To investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.
Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki   +3 more
doaj   +1 more source

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis

Frontiers in Endocrinology, 2023
PurposeTo assess the alterations in bone mineral density and bone turnover marker concentrations following the administration of denosumab and romosozumab therapies in patients with osteoporosis.MethodsPubMed was searched for studies published until ...
Mingwei Hu, Yifan Zhang, Jianjun Guo, Cuicui Guo, Xue Yang, Xue Ma, Hao Xu, Shuai Xiang   +7 more
doaj   +1 more source

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study [PDF]

Endocrinology and Metabolism, 2021
Background This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis. Methods Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores ≤−2.5 ...
Ki-Hyun Baek, Yoon-Sok Chung, Jung-Min Koh, In Joo Kim, Kyoung Min Kim, Yong-Ki Min, Ki Deok Park, Rajani Dinavahi, Judy Maddox, Wenjing Yang, Sooa Kim, Sang Jin Lee, Hyungjin Cho, Sung-Kil Lim   +13 more
doaj   +1 more source

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals

JBMR Plus, 2021
Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy.
Felicia Cosman, Cesar Libanati, Cynthia Deignan, Zhigang Yu, Zhenxun Wang, Serge Ferrari, Jens‐Erik Beck Jensen, Pilar Peris, Francesco Bertoldo, Eric Lespessailles, Eric Hesse, Steven R Cummings   +11 more
doaj   +1 more source

Successful treatment of humeral shaft nonunion with romosozumab: A case report

Trauma Case Reports, 2022
Romosozumab is a humanized monoclonal anti-sclerostin antibody (Scl-Ab) that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption.
Sang Yang Lee, Keikichi Kawasaki, Katsunori Inagaki   +2 more
doaj   +1 more source

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report

Bone Reports, 2020
Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii, Kosuke Ebina, Kazuma Kitaguchi, Hideki Yoshikawa   +3 more
doaj   +1 more source